Melt Pharmaceuticals
San Diego, US · Founded 2018 · Delaware corporation
Founders & leadership
GM
Gregory MadisonExecutive
MB
Mark BaumNamed on SEC filing
JB
John BerdahlNamed on SEC filing
Board
AB
Andrew BollBoard director
LD
Larry DillahaBoard director
Reported raises · per SEC filings
Form D private placements$53.7M disclosed across 2 rounds · 2019–2023
▶$42.3MraisedApr 2024 · 309 investors · PharmaceuticalsRule 506(b)
▶$42.3MraisedApr 2024 · 309 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Larry DillahaExecutive Officer, Director
- Brad OsborneExecutive Officer
- Offering amount
- $47.8M
- Amount sold
- $42.3M
- Sales commissions
- $1.8M
- Placement agents
- Newbridge Securities Corporation
- First sale
- Jul 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$11.4MraisedApr 2019 · 165 investors · PharmaceuticalsRule 506(b)
▶$11.4MraisedApr 2019 · 165 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Larry DillahaDirector
- Andrew BollDirector
- Mark BaumDirector
- Gregory MadisonExecutive Officer, Director
- John BerdahlDirector
- Offering amount
- $25.8M
- Amount sold
- $11.4M
- Sales commissions
- $1.8M
- Placement agents
- Newbridge Securities Corporation
- First sale
- Jan 2019
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- How much funding has Melt Pharmaceuticals raised?
- Melt Pharmaceuticals has disclosed $53.7M raised across 2 rounds.
- Where is Melt Pharmaceuticals headquartered?
- Melt Pharmaceuticals is headquartered in San Diego, US.